Source: International Congress 2017 – State of the art session: "Lung cancer"



Rating:

Share or cite this content

Citations should be made in the following way:
Nir Peled (Hod Hasharon, Israel). Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond. International Congress 2017 – State of the art session: "Lung cancer"

Member's Comments

Bernard Yung - 01.10.2017 16:09
State of the art review of am
Ultra fast moving train!

Related content which might interest you: 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Is MIF -173G/C polymorphism associated with in non-small cell lung cancer (NSCLC) susceptibility? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Lung cancer Source: Respipedia Article Year: 2018 Advanced non-small cell lung cancer (NSCLC): observation of chemotherapy in 5 European countries Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis Source: International Congress 2015 – How to treat brain metastases Year: 2015 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Surgical treatment of N2 non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 39s Year: 2004 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020